haloperidol has been researched along with Tardive Dystonia in 22 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tardive dyskinesia (TD)." | 8.02 | Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia. ( Fang, CH; Lin, YW; Soung, HS; Tseng, HC; Wang, MH; Yang, CC, 2021) |
| "Tardive dyskinesia (TD) is associated with the use of antipsychotic drugs such as D2 antagonist haloperidol (HP)." | 7.85 | Antioxidant effects of rice bran oil mitigate repeated haloperidol-induced tardive dyskinesia in male rats. ( Haleem, DJ; Samad, N, 2017) |
| "Effect of administration of Rice bran oil (RBO) was evaluated on haloperidol elicited tardive dyskinesia in rats." | 7.83 | Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats. ( Haleem, DJ; Haleem, MA; Samad, N, 2016) |
| "Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD)." | 7.83 | Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions. ( Haleem, DJ; Samad, N; Yasmin, F, 2016) |
| "Tardive dyskinesia (TD) is a movement disorder that appears after chronic use of drugs that block dopaminergic receptors such as antipsychotics." | 5.62 | PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. ( Guimarães, FS; Prado, DDS; Sonego, AB, 2021) |
| "Haloperidol is a first-generation antipsychotic used in the treatment of psychoses, especially schizophrenia." | 5.51 | Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats. ( Cavalcanti, DMLP; Cavalcanti, JRLP; da Silva, ANA; da Silva, MSM; de Araújo, DP; de Sales, LGP; Guzen, FP; Pinheiro, FI, 2019) |
| " This study aimed to investigate behavioral and neurochemical effects of supplementation with LA (100 mg/kg) and ω-3 (1 g/kg) in the treatment of TD induced by chronic use of haloperidol (HAL) (1 mg/kg) in rats." | 5.46 | Behavioral and neurochemical effects of alpha lipoic acid associated with omega-3 in tardive dyskinesia induced by chronic haloperidol in rats. ( Barbosa, MDA; Camboim, TGM; Cavalcanti, JRLP; de Araújo, DP; de Sousa, RC; Guzen, FP; Lucena, EES; Oliveira, LC; Silva, APM; Silva, CDF, 2017) |
| "Rats treated with haloperidol decanoate (HAL; 21mg/kg every 3weeks, IM) for 12weeks were concurrently treated with LA (10 or 20mg/kg, PO)." | 5.46 | Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. ( Andreazza, AC; Fletcher, PJ; Lister, J; Navaid, B; Nesarajah, Y; Nobrega, JN; Remington, G; Teo, C; Wilson, AA; Wilson, VS, 2017) |
| "Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tardive dyskinesia (TD)." | 4.02 | Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia. ( Fang, CH; Lin, YW; Soung, HS; Tseng, HC; Wang, MH; Yang, CC, 2021) |
| "Tardive dyskinesia (TD) is associated with the use of antipsychotic drugs such as D2 antagonist haloperidol (HP)." | 3.85 | Antioxidant effects of rice bran oil mitigate repeated haloperidol-induced tardive dyskinesia in male rats. ( Haleem, DJ; Samad, N, 2017) |
| " tardive dyskinesia) treatment with antipsychotics, including haloperidol, varies substantially among people." | 3.85 | Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. ( Miksys, S; Nobrega, JN; Remington, G; Tolledo, EC; Tyndale, RF; Wadji, FB, 2017) |
| "Effect of administration of Rice bran oil (RBO) was evaluated on haloperidol elicited tardive dyskinesia in rats." | 3.83 | Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats. ( Haleem, DJ; Haleem, MA; Samad, N, 2016) |
| "Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD)." | 3.83 | Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions. ( Haleem, DJ; Samad, N; Yasmin, F, 2016) |
| " It is predominantly associated with the long-term use of antipsychotic medications, particularly typical or first-generation antipsychotic drugs such as haloperidol." | 1.91 | Bacillus Calmette-Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats. ( Ahmad, SF; Jamwal, S; Kumar, P; Singh, R; Upadhayay, S; Yedke, NG, 2023) |
| "Tardive dyskinesia (TD) is a movement disorder that appears after chronic use of drugs that block dopaminergic receptors such as antipsychotics." | 1.62 | PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. ( Guimarães, FS; Prado, DDS; Sonego, AB, 2021) |
| "Tardive dyskinesia is a delayed and potentially irreversible motor complication arising from chronic exposure to antipsychotic drugs." | 1.51 | Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates. ( Blanchet, PJ; Cyr, M; Diaz, J; Hernandez, G; Lévesque, D; Mahmoudi, S, 2019) |
| "Haloperidol is a first-generation antipsychotic used in the treatment of psychoses, especially schizophrenia." | 1.51 | Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats. ( Cavalcanti, DMLP; Cavalcanti, JRLP; da Silva, ANA; da Silva, MSM; de Araújo, DP; de Sales, LGP; Guzen, FP; Pinheiro, FI, 2019) |
| "Mice treated with haloperidol showed an increase in microglial activation and inflammatory mediators in the striatum." | 1.48 | Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. ( Cunha, TM; Del Bel, EA; Guimarães, FS; Prado, DS; Raisman-Vozari, R; Sepulveda-Diaz, JE; Sonego, AB; Tirapelli, CR; Vale, GT, 2018) |
| " This study aimed to investigate behavioral and neurochemical effects of supplementation with LA (100 mg/kg) and ω-3 (1 g/kg) in the treatment of TD induced by chronic use of haloperidol (HAL) (1 mg/kg) in rats." | 1.46 | Behavioral and neurochemical effects of alpha lipoic acid associated with omega-3 in tardive dyskinesia induced by chronic haloperidol in rats. ( Barbosa, MDA; Camboim, TGM; Cavalcanti, JRLP; de Araújo, DP; de Sousa, RC; Guzen, FP; Lucena, EES; Oliveira, LC; Silva, APM; Silva, CDF, 2017) |
| "Rats treated with haloperidol decanoate (HAL; 21mg/kg every 3weeks, IM) for 12weeks were concurrently treated with LA (10 or 20mg/kg, PO)." | 1.46 | Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. ( Andreazza, AC; Fletcher, PJ; Lister, J; Navaid, B; Nesarajah, Y; Nobrega, JN; Remington, G; Teo, C; Wilson, AA; Wilson, VS, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 6 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Kadir, A | 1 |
| Singh, J | 1 |
| Rahi, V | 1 |
| Kumar, P | 2 |
| Misawa, F | 1 |
| Fujii, Y | 1 |
| Takeuchi, H | 1 |
| Uslu, ET | 1 |
| Mengi, M | 1 |
| Beyazyüz, E | 1 |
| Çelikkol, A | 1 |
| Albayrak, Y | 1 |
| Yedke, NG | 1 |
| Upadhayay, S | 1 |
| Singh, R | 1 |
| Jamwal, S | 1 |
| Ahmad, SF | 1 |
| Wei, YP | 1 |
| Yang, SW | 1 |
| Wang, MH | 2 |
| Yang, CC | 1 |
| Tseng, HC | 2 |
| Fang, CH | 1 |
| Lin, YW | 1 |
| Soung, HS | 2 |
| Sonego, AB | 2 |
| Prado, DDS | 1 |
| Guimarães, FS | 2 |
| de Araújo, DP | 2 |
| Camboim, TGM | 1 |
| Silva, APM | 1 |
| Silva, CDF | 1 |
| de Sousa, RC | 1 |
| Barbosa, MDA | 1 |
| Oliveira, LC | 1 |
| Cavalcanti, JRLP | 2 |
| Lucena, EES | 1 |
| Guzen, FP | 2 |
| Samad, N | 3 |
| Haleem, DJ | 4 |
| Miksys, S | 1 |
| Wadji, FB | 1 |
| Tolledo, EC | 1 |
| Remington, G | 2 |
| Nobrega, JN | 2 |
| Tyndale, RF | 1 |
| Lévesque, C | 1 |
| Hernandez, G | 2 |
| Mahmoudi, S | 2 |
| Calon, F | 1 |
| Gasparini, F | 1 |
| Gomez-Mancilla, B | 1 |
| Blanchet, PJ | 2 |
| Lévesque, D | 2 |
| Chen, CN | 1 |
| Chang, KC | 1 |
| Prado, DS | 1 |
| Vale, GT | 1 |
| Sepulveda-Diaz, JE | 1 |
| Cunha, TM | 1 |
| Tirapelli, CR | 1 |
| Del Bel, EA | 1 |
| Raisman-Vozari, R | 1 |
| Cyr, M | 1 |
| Diaz, J | 1 |
| Khan, MM | 1 |
| Xiao, J | 1 |
| Hollingsworth, TJ | 1 |
| Patel, D | 1 |
| Selley, DE | 1 |
| Ring, TL | 1 |
| LeDoux, MS | 1 |
| Cavalcanti, DMLP | 1 |
| de Sales, LGP | 1 |
| da Silva, MSM | 1 |
| da Silva, ANA | 1 |
| Pinheiro, FI | 1 |
| Shi, J | 1 |
| Tan, YL | 1 |
| Wang, ZR | 1 |
| An, HM | 1 |
| Li, J | 1 |
| Wang, YC | 1 |
| Lv, MH | 1 |
| Yan, SX | 1 |
| Wu, JQ | 1 |
| Soares, JC | 1 |
| Yang, FD | 1 |
| Zhang, XY | 1 |
| Lister, J | 1 |
| Andreazza, AC | 1 |
| Navaid, B | 1 |
| Wilson, VS | 1 |
| Teo, C | 1 |
| Nesarajah, Y | 1 |
| Wilson, AA | 1 |
| Fletcher, PJ | 1 |
| Haleem, MA | 1 |
| Bordia, T | 1 |
| Zhang, D | 1 |
| Perez, XA | 1 |
| Quik, M | 1 |
| Malik, T | 1 |
| Hasan, S | 1 |
| Pervez, S | 1 |
| Fatima, T | 1 |
| Yasmin, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response[NCT03495024] | Phase 4 | 10 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 other studies available for haloperidol and Tardive Dystonia
| Article | Year |
|---|---|
Berberine Ameliorate Haloperidol and 3-Nitropropionic Acid-Induced Neurotoxicity in Rats.
Topics: Animals; Antioxidants; Berberine; Catalase; Haloperidol; Huntington Disease; Motor Activity; Neuropr | 2022 |
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; | 2022 |
The effects of sigma-1 agonist fluvoxamine on experimental induced tardive dyskinesia model in rats.
Topics: Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Dyskinesias; Fluvoxamine; Haloperi | 2023 |
Bacillus Calmette-Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats.
Topics: Animals; Antipsychotic Agents; BCG Vaccine; Behavior, Animal; Haloperidol; Rats; Tardive Dyskinesia | 2023 |
Simultaneous bilateral ulnar neuropathy: an unusual complication caused by neuroleptic treatment-induced tardive dyskinesia: A Case Report.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Middle Aged; Schi | 2019 |
Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesias; Flavanones; Haloperidol; Humans; | 2021 |
PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice.
Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Behavior, Animal; Cannabidiol; Cognitive Dysf | 2021 |
Behavioral and neurochemical effects of alpha lipoic acid associated with omega-3 in tardive dyskinesia induced by chronic haloperidol in rats.
Topics: Animals; Behavior, Animal; Drug Interactions; Fatty Acids, Omega-3; Haloperidol; Lipid Peroxidation; | 2017 |
Antioxidant effects of rice bran oil mitigate repeated haloperidol-induced tardive dyskinesia in male rats.
Topics: Animals; Antioxidants; Behavior, Animal; Catalase; Corpus Striatum; Disease Models, Animal; Glutathi | 2017 |
Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms.
Topics: Animals; Brain; Catalepsy; Cytochrome P450 Family 2; Haloperidol; Liver; Male; Microinjections; Nico | 2017 |
Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Clozapine; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dys | 2017 |
Protective Effect of L-Theanine on Haloperidol-Induced Orofacial.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesias; Glutamates; Haloperidol; Lipid Peroxi | 2018 |
Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Brain; Cannabidiol; Corpus Striatum; | 2018 |
Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates.
Topics: Animals; beta-Arrestin 2; Cebus; Clozapine; Dopamine and cAMP-Regulated Phosphoprotein 32; G-Protein | 2019 |
Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidol.
Topics: Animals; Brain; Dopamine Antagonists; Female; Genomic Instability; GTP-Binding Protein alpha Subunit | 2019 |
Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Haloperidol; Ma | 2019 |
Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model.
Topics: Animals; Antioxidants; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; G | 2016 |
Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia.
Topics: Aldehydes; Analysis of Variance; Animals; Antioxidants; Antipsychotic Agents; Haloperidol; Male; Mal | 2017 |
Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Dyskinesias; Haloperidol; Hyd | 2016 |
Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Channelrhodopsins; Choline O-Acetyltransferase; Cholinergic Neurons; | 2016 |
Nigella sativa Oil Reduces Extrapyramidal Symptoms (EPS)-Like Behavior in Haloperidol-Treated Rats.
Topics: Animals; Antipsychotic Agents; Astrocytes; Basal Ganglia Diseases; Caudate Nucleus; Dyskinesia, Drug | 2016 |
Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Brain; Disease Models, Animal; Ha | 2016 |